Australia Autoimmunity Diagnostics Market (2025-2030)
The Australia Autoimmunity Diagnostics Market was valued at $67.7 Million in 2025 and projected to reach to $112.3 Million by 2030, representing a compound annual growth rate of 8.8%. Australia's autoimmunity diagnostics market is positioned for sustained expansion through 2030, driven by heightened disease awareness and improved access to diagnostic testing across urban and regional healthcare providers.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Australia Autoimmunity Diagnostics Market Trends and Insights
- This expansion reflects Australia's advanced healthcare infrastructure and rising prevalence of autoimmune disorders across the population.
- Australia's market growth rate of 8.8% CAGR outpaces the global average, driven by increasing diagnostic awareness and improved access to specialized testing facilities. The Australian market benefits from strong regulatory frameworks and a well-established pathology network that supports early detection and management of autoimmune conditions.
- Australia's healthcare system prioritizes precision diagnostics, enabling clinicians to identify autoimmune diseases with greater accuracy.
- Between 2025 and 2030, Australia is expected to see heightened investment in laboratory automation and multiplex testing platforms, further accelerating market penetration across metropolitan and regional centers..
Key Market Statistics
- CAGR (2025-2030) 8.8% CAGR
- Market Size, 2025 ~USD 67.7 Million
- Forecast, 2030 ~USD 112.3 Million
- Country Australia
Australia Autoimmunity Diagnostics Market Overview
Market Valuation Growth :
Australia's autoimmunity diagnostics market is valued at USD 67.7 million in 2025, with strong projection to reach USD 112.3 million by 2030, representing a 65.8% total growth over five years.
Above-Global Growth Rate :
Australia's market CAGR of 8.8% significantly outpaces the global average of 8.3%, indicating stronger regional demand and market penetration compared to international benchmarks.
Advanced Healthcare Infrastructure :
Australia's sophisticated healthcare system, including Medicare coverage and advanced diagnostic facilities, supports rapid adoption of autoimmunity diagnostic technologies and testing protocols.
Rising Autoimmune Prevalence :
Increasing prevalence of autoimmune disorders across the Australian population drives demand for early detection and accurate diagnostic solutions in clinical and pathology settings.
Australia Autoimmunity Diagnostics Market Dynamics
- The market benefits from Australia's strong pathology sector and increasing investment in precision medicine initiatives.
- Healthcare providers are increasingly adopting advanced serological and molecular diagnostic platforms to enhance patient outcomes and reduce diagnostic delays.
- Government support for chronic disease management and private healthcare growth further accelerates market adoption.
- By 2030, Australia's market is expected to mature as a key regional hub for autoimmunity diagnostics innovation and clinical implementation..
Related Ecosystem
Analytical And Scientific Instrumentation
- Environmental Testing
- Gas Chromatography
- Polymerase Chain Reaction (PCR)
- Automated Liquid Handling Systems
- Flow Cytometry
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Agilent Technologies, Inc.
- Merck KGaA
- Shimadzu Corporation
In Vitro Diagnostics
- Polymerase Chain Reaction (PCR)
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Dna Microarrays
- Assay Kits
- Microarrays
- ROCHE HOLDINGS AG
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Abbott Laboratories
- Biomerieux s.a.
Key Takeaways
- Australia's autoimmunity diagnostics market is valued at USD 67.7 million in 2025 and will reach USD 112.3 million by 2030, representing 65.8% growth over five years.
- Australia's 8.8% CAGR exceeds the global average of 8.3%, positioning the country as a high-growth market within the Asia Pacific region.
- Australia's mature healthcare system and strong pathology infrastructure support widespread adoption of advanced autoimmune diagnostic technologies.
- Australia's market expansion is driven by rising autoimmune disease prevalence, increased clinical awareness, and investment in laboratory automation and multiplex testing.
Autoimmunity Diagnostics Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | AUTOANTIBODIES AND IMMUNOLOGIC TESTS (Test Type) |
| Forecast Period | 2025-2030 |
| Growth Rate | CAGR of 8.3% from 2025 to 2030 |
| Largest Segment | CONSUMABLES (Product) |
| Market Size Base Year (Billions) | ~USD 5.57 (2025) |
| Revenue Forecast (Billions) | ~USD 8.29 (2030) |
| Segments Covered | Product, Test Type, Disease Type, Type, End User |
Australia Autoimmunity Diagnostics Market Report Segmentation
5 segment dimensions are covered across the global market.
By Product
- Consumables
- Instruments
By Test Type
- Autoantibodies And Immunologic Tests
- Inflammatory Tests
- Other Tests
- Routine Laboratory Tests
- Urinalysis Tests
By Disease Type
- Organ-Specific Autoimmune Diseases
- Systemic Autoimmune Diseases
By Type
- Celiac Disease
- Inflammatory Bowel Disease
- Multiple Sclerosis
- Other Organ-Specific Autoimmune Diseases
- Other Systemic Autoimmune Diseases
- Psoriasis
- Rheumatoid Arthritis
- Systemic Lupus Erythematosus
- Type-1 Diabetes
By End User
- Clinical Laboratories
- Hospitals & Clinics
- Other End Users
AUSTRALIA: AUTOIMMUNITY DIAGNOSTICS MARKET, BY END USER, 2023–2031
| Segment | 2023 | 2024 | 2025 | 2026 | 2028 | 2029 | 2030 | 2031 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| CLINICAL LABORATORIES | 37.5 | 39.8 | 42.6 | 45.8 | 54 | 59.2 | 65.3 | 72.9 | 9.4 |
| HOSPITALS & CLINICS | 33 | 34.7 | 36.7 | 39.1 | 45.1 | 48.9 | 53.5 | 59.1 | 8.3 |
| OTHER END USERS | 13.8 | 14.2 | 14.7 | 15.4 | 17.1 | 18.3 | 19.6 | 21.3 | 6.3 |
| TOTAL | 84.2 | 88.7 | 94.1 | 100.3 | 116.1 | 126.3 | 138.5 | 153.3 | 8.5 |
Target Audience
- In Vitro Diagnostics Manufacturers : IVD companies need Australia-specific market data to develop localized product strategies, understand reimbursement pathways, and identify distribution partnerships within Australia's pathology networks.
- Healthcare Investment Firms : Private equity and venture capital investors require detailed Australian market metrics to evaluate investment opportunities in diagnostic companies, assess regional growth potential, and benchmark valuations.
- Pathology Service Providers : Australian pathology laboratories and diagnostic centers need market intelligence to optimize service offerings, justify capital investments in diagnostic equipment, and plan capacity expansion.
- Medical Device Distributors : Regional distributors and importers require Australia-focused market data to negotiate supplier agreements, forecast demand, and develop go-to-market strategies for diagnostic products.
- Healthcare Policy & Regulatory Bodies : Government agencies and health authorities use market data to inform reimbursement policies, diagnostic guidelines, and healthcare resource allocation for autoimmunity testing in Australia.
Reasons to Buy this Report
- Market-Specific Sizing Data : Access precise valuation figures for Australia's autoimmunity diagnostics market with detailed 2025-2030 forecasts, enabling accurate budget allocation and revenue projections for regional operations.
- Competitive Positioning Intelligence : Understand Australia's 8.8% CAGR advantage over global markets to identify growth opportunities and competitive advantages specific to the Australian healthcare landscape and regulatory environment.
- Regional Healthcare Insights : Gain actionable intelligence on Australia's advanced healthcare infrastructure, Medicare reimbursement landscape, and pathology sector dynamics to inform market entry and expansion strategies.
- Disease Prevalence Analysis : Leverage data on rising autoimmune disorder prevalence across Australian populations to identify high-demand diagnostic segments and target clinical settings for product development and marketing.
- Strategic Investment Decisions : Make informed investment and partnership decisions with comprehensive market outlook through 2030, including growth drivers, adoption trends, and emerging opportunities in Australian diagnostics.
Frequently asked questions
What is the current size of Australia's autoimmunity diagnostics market?
Australia's autoimmunity diagnostics market is valued at USD 67.7 million in 2025 and is projected to grow to USD 112.3 million by 2030.
What is the growth rate for Australia's autoimmunity diagnostics market?
Australia's autoimmunity diagnostics market is growing at a CAGR of 8.8% from 2025 to 2030, outpacing the global average of 8.3%.
What factors are driving growth in Australia's autoimmunity diagnostics market?
Growth in Australia is driven by rising autoimmune disease prevalence, increased diagnostic awareness, strong healthcare infrastructure, and investment in laboratory automation and multiplex testing platforms.
How does Australia's market compare to the global autoimmunity diagnostics market?
Australia's 8.8% CAGR exceeds the global CAGR of 8.3%, indicating that Australia is a faster-growing market within the broader global landscape.
What role does Australia's healthcare system play in market growth?
Australia's mature healthcare system, strong regulatory frameworks, and well-established pathology network support early detection and widespread adoption of advanced autoimmune diagnostic technologies.
RESEARCH METHODOLOGY
The study involved estimating activities to determine the current size of the autoimmunity diagnostics market. Exhaustive secondary research was done to collect information on the autoimmunity diagnostics industry. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the autoimmunity diagnostics market.
Secondary Research
Various sources were utilized to gather information for this study in the secondary research process. These sources included company annual reports, press releases, and investor presentations; white papers; certified publications; articles by recognized authors; reputable websites; and information from regulatory bodies and databases, such as D&B Hoovers, Bloomberg Business, and Factiva.
Primary Research
In the primary research process, various sources from both the supply & demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess prospects.
The following is a breakdown of the primary respondents:
Note 1: Others include sales, marketing, and product managers.
Note 2: Companies are classified into tiers based on their total revenues. As of 2024, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = < USD 10 million.
To know about the assumptions considered for the study, download the pdf brochure
| COMPANY NAME | DESIGNATION |
|---|---|
| Abbott Laboratories (US) | Product Specialist |
| Thermo Fisher Scientific Inc. (US) | Clinical Sales Specialist |
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the autoimmunity diagnostics market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry were identified through extensive secondary research.
- Primary and secondary research determined the revenues generated by leading players operating in the autoimmunity diagnostics market.
- All percentage shares, splits, and breakdowns were determined using secondary sources and verified through primary sources.
The research methodology used to estimate the market size includes the following:
Data Triangulation
The total market was split into several segments after arriving at the overall market size by applying the abovementioned process. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Autoimmune diseases are defined as a medical condition in which an individual's immune system produces antibodies that attack the body's normal tissues. autoimmunity diagnostics systematically identifies autoimmune disorders through clinical assessment and laboratory investigations to detect immune system dysfunction. This process typically involves routine laboratory testing, measurement of systemic inflammatory markers, detection of disease-specific autoantibodies, urinalysis, and other specialized immunologic assays.
Stakeholders
- Manufacturers & distributors of autoimmunity diagnostics products
- Clinical laboratories
- Hospitals
- Research institutes
- Government associations
- Venture capitalists & investors
Report Objectives
- To define, describe, segment, and forecast the global autoimmunity diagnostics market, by product, test type, disease type, end user, and region
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall autoimmunity diagnostics market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
- To benchmark players within the market using the proprietary Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business and product excellence
Get the Full Autoimmunity Diagnostics Market Report
Full forecast, segment splits, and company analysis for all Autoimmunity Diagnostics Market.
- Rest Of Asia Pacific Autoimmunity Diagnostics Market
- US Autoimmunity Diagnostics Market
- Canada Autoimmunity Diagnostics Market
- UK Autoimmunity Diagnostics Market
- Germany Autoimmunity Diagnostics Market
- France Autoimmunity Diagnostics Market
- Italy Autoimmunity Diagnostics Market
- Spain Autoimmunity Diagnostics Market
- China Autoimmunity Diagnostics Market
- Japan Autoimmunity Diagnostics Market
- India Autoimmunity Diagnostics Market
- Rest Of Europe Autoimmunity Diagnostics Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
